$4.85
+0.15 (+3.19%)
Open$4.60
Previous Close$4.70
Day High$5.00
Day Low$4.58
52W High$20.00
52W Low$3.29
Volume—
Avg Volume225.2K
Market Cap14.85M
P/E Ratio—
EPS$-11.84
SectorBiotechnology
Analyst Ratings
Buy
11 analysts
Price Target
+649.1% upside
Current
$4.85
$4.85
Target
$36.33
$36.33
$21.56
$36.33 avg
$42.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.14M | 4.29M | 4.24M |
| Net Income | -270,468 | -254,054 | -270,426 |
| Profit Margin | -6.5% | -5.9% | -6.4% |
| EBITDA | -483,031 | -431,767 | -494,923 |
| Free Cash Flow | -204,723 | -222,413 | -294,472 |
| Rev Growth | -4.9% | +3.8% | -2.6% |
| Debt/Equity | 0.13 | 0.14 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |